Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-A12 in Advanced Hepatocellular Carcinoma
NCT00639509Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2008
- Primary completion
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cixutumumab in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Primary endpoints: Progression-Free Survival Rate at 4 months and Best Overall Response Rate. Started Mar 2008; status: completed.
02
Drugs
cixutumumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00639509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00639509.